|
Post by mnkdfann on Nov 6, 2019 8:12:39 GMT -5
Summary at SA reads:
MannKind EPS beats by $0.02, misses on revenue Nov. 6, 2019 8:03 AM ET|About: MannKind Corporation (MNKD)|By: Mohit Manghnani, SA News Editor
MannKind (NASDAQ:MNKD): Q3 GAAP EPS of -$0.05 beats by $0.02.
Revenue of $14.6M (+226.6% Y/Y) misses by $0.62M.
|
|
|
Post by mnkdfann on Nov 5, 2019 18:04:52 GMT -5
Also: www.diabetesselfmanagement.com/about-diabetes/general-diabetes-information/diabetes-in-the-military/"While not all medical conditions disqualify a person from joining the military, many do, and any type of diabetes generally does. Developing diabetes while already serving in the military, however, is not automatic grounds for separation (retirement) from the military. Several hundred service members (out of more than 1.4 million currently serving) are diagnosed with diabetes each year. Between 1997 and 2007, fewer than 6% of diabetes diagnoses were Type 1 diabetes, 80% were Type 2 diabetes, and the remaining 14% were not consistently reported as either Type 1 or Type 2 diabetes. Because active service members have mandatory medical examinations and free access to health care, it is thought that there are few undiagnosed cases of diabetes among military personnel. Service members who develop diabetes and cannot maintain an HbA1c level below 7% without medication are referred to a medical evaluation board, which assesses their medical fitness and makes recommendations about follow-up care."
|
|
|
Post by mnkdfann on Nov 4, 2019 16:15:35 GMT -5
Agree Slugworth. A 5% stake announcement by UTHR could turn MNKD's world right side up immediately. I'm no expert on UTHR's business practices. Does it have any history of taking 'stakes' in companies it works with? Or does it generally just license and do milestone agreements?
|
|
|
Post by mnkdfann on Nov 2, 2019 22:54:41 GMT -5
There are lots of technical day/swing traders who only take a cursory look at the company behind the ticker. With 4 Buy ratings and upwards movement MNKD may start generating some volume in the near-term. Even better than the previously reported 141 million shares of two trading days ago?
|
|
|
Post by mnkdfann on Nov 1, 2019 20:33:19 GMT -5
Yahoo finance says that MNKD volume yesterday was 141 million shares. Even for end-of-month rebalancing, isn't that incredibly large? ... maybe a mistake by yahoo? Probably someone initiating a new short position.
|
|
|
Post by mnkdfann on Oct 30, 2019 20:52:04 GMT -5
Taking into account the different time zone, I'll be in the midst of my morning ablutions (brushing teeth, taking a shower, having a poop). I don't agree with the order of your ablutions. It was ordered for optimal humour, not by time sequence. And if you see me posting in a shoutbox during the call, you know where I'll be posting from.
|
|
|
Post by mnkdfann on Oct 30, 2019 20:42:53 GMT -5
I just don't like the AM calls because I'm actually working Taking into account the different time zone, I'll be in the midst of my morning ablutions (brushing teeth, taking a shower, having a poop).
|
|
|
Post by mnkdfann on Oct 30, 2019 7:41:15 GMT -5
FWIW, I'm not sure I would say MNKD is 'highly' volatile but it does have a relatively higher than normal volatility.
"One measure of the relative volatility of a particular stock to the market is its beta (β). A beta approximates the overall volatility of a security's returns against the returns of a relevant benchmark (usually the S&P 500 is used). For example, a stock with a beta value of 1.1 has historically moved 110% for every 100% move in the benchmark, based on price level."
MNKD's beta is about 2.17, so it moves much more than the overall market. I understand that from day to day it may not seem like it, but when MNKD moves it moves.
One can also look at the share price volatility implied through the MNKD options, and those are also high. At least, they are certainly not what I would call low. They are certainly generally much higher than, say, those for UTHR.
|
|
|
Post by mnkdfann on Oct 30, 2019 7:34:12 GMT -5
UTHR reported this morning, perhaps people were expecting a MNKD shout-out and some gains from that. Hence the rise late in the day yesterday.
|
|
|
Post by mnkdfann on Oct 29, 2019 0:52:40 GMT -5
Fumaryl diketopiperazine based effervescent microparticles to escape macrophage phagocytosis for enhanced treatment of pneumonia via pulmonary delivery That can replace supercalifragilisticexpialidocious if they ever remake Mary Poppins. Oh, wait, they just sort of did.
|
|
|
Post by mnkdfann on Oct 25, 2019 23:42:53 GMT -5
Or, "as Mike contends, it simply wasn't a good business deal". I suppose it depends on who you believe. From what I've been presented, I've personally no reason to believe Mike and the board were not justified in deciding that the deal was lacking. (Mike previously posted why he / they thought the deal was not in Mannkind's best interests.) Do you mind refreshing our memories as to why the UAE deal was not in the best interest of MNKD? Thanks I remember Mike saying so in a post on this forum, but I do not recall with 100% confidence what his reasons were. Okay, I searched just now and found one of his relevant posts. Rather, I found a post of his that someone quoted, as it appears his original post was deleted. At least, that is how it looks. Anyway, here is the link: mnkd.proboards.com/post/182066The relevant bits are: "The deal in the middle east that we walked away from wasn’t going to generate much value versus distraction/risk due to global reference pricing . There were people trying to put something together with our old CEO again without any financials or a valid partner who distributed pharmaceutical products/ sales reps etc. I wasn’t part of that deal discussion and walked away when I became CEO bc we weren’t confident there were any meaningful financial terms and didn’t feel comfortable with players involved." Like everyone else, I have biases. I suppose if one is biased toward believing what Vdex says, Mike's argument is weak. OTOH, the fact that HfM and crew have aligned themselves with MK (along with other facts) makes me question their business aptitude, at least when it comes to advising what is best for Mannkind.
|
|
|
Post by mnkdfann on Oct 25, 2019 21:36:06 GMT -5
Exactly! Castagna could have grabbed the brass ring by bringing in the UAE deal. It need not have been exclusive which would have left the door open for larger regional partnerships in the future of which, obviously, none have materialized. Or, "as Mike contends, it simply wasn't a good business deal". I suppose it depends on who you believe. From what I've been presented, I've personally no reason to believe Mike and the board were not justified in deciding that the deal was lacking. (Mike previously posted why he / they thought the deal was not in Mannkind's best interests.)
|
|
|
Post by mnkdfann on Oct 25, 2019 14:31:29 GMT -5
Bill was working WITH MannKind and not trying to fly "under the radar" as this poster accuses them of doing. Mr. McCullough has business contacts worldwide and hooked up some of them with Joseph Saldanha, who was MannKind's VP of Marketing. People in the UAE expressed interest and Bill brought them to MannKind. How is that flying under the radar or somehow indicates a nefarious intent? Incidentally, for those of you who didn't know Joe, here is his bio (contained in a MannKind press release from April 19, 2016): "Mr. Saldanha has worked in the diabetes space for over 13 years, in both U.S. and global roles. He has experience marketing oral anti-diabetic medications, insulins (both injectable and inhaled), and medical devices. Mr. Saldanha commercialized Sanofi's Lantus® in the Intercontinental Region. After returning to the U.S., he was part of the team that commercialized the Lantus SoloSTAR® pen. In addition to heading up Sanofi's strategy and medical education teams, he was responsible for all hospital business. Mr. Saldanha launched an initiative with Certified Diabetes Educators® to train patients in diabetes and the appropriate use of insulin. Prior to that, Mr. Saldanha served as Director of Business Development for the insulin delivery device business at Johnson and Johnson Diabetes (LifeScan®/Animas®). More recently, he worked in the biosimilars business with Pfizer in New York. Mr. Saldanha holds a Bachelor of Science from Drexel University and a Master of Science from the University of Pennsylvania."Today Mr. Saldanha is apparently Chief Business Officer, Valeritas Holdings Inc. That looks to me like a big step down (compared to Mannkind). I'm willing to believe Mr. Saldanha is a good guy and does good work. I've no reason to believe otherwise. But his career trajectory suggests to me that maybe his peers and his industry don't put him on the same pedestal some others have.
|
|
|
Post by mnkdfann on Oct 25, 2019 7:28:14 GMT -5
"The insulin comes in a cartridge like this; it is placed in the device almost like a puzzle piece," said Dr. Michelle Welch, of Diabetes and Metabolism Specialists San Antonio. mydmsweightloss.com/our-team/
|
|
|
Post by mnkdfann on Oct 24, 2019 19:15:03 GMT -5
www.tipranks.com/analysts/brandon-folkesRanked #5,266 out of 5,575 Analysts Average return of -9.2% (negative 9.2% return). Based on his track record, I'd be more optimistic if he was calling it a short.
|
|